ABIO ARCA Biopharma Inc

USD 3.35 0.00 0
Icon

ARCA Biopharma Inc (ABIO) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 3.35

0.00 (0.00)%

USD 0.05B

0.02M

N/A

USD 3.00 (-10.45%)

Icon

ABIO

ARCA Biopharma Inc (USD)
COMMON STOCK | NSD
USD 3.35
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.05B

USD 3.00 (-10.45%)

USD 3.35

ARCA Biopharma Inc (ABIO) Stock Forecast

N/A

Based on the ARCA Biopharma Inc stock forecast from 0 analysts, the average analyst target price for ARCA Biopharma Inc is not available over the next 12 months. ARCA Biopharma Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ARCA Biopharma Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, ARCA Biopharma Inc’s stock price was USD 3.35. ARCA Biopharma Inc’s stock price has changed by -2.62% over the past week, +1.21% over the past month and +65.84% over the last year.

No recent analyst target price found for ARCA Biopharma Inc
No recent average analyst rating found for ARCA Biopharma Inc

Company Overview ARCA Biopharma Inc

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has...Read More

https://www.albioma.com

Tour Opus 12, Paris, France, 92914

4

December

USD

USA

Adjusted Closing Price for ARCA Biopharma Inc (ABIO)

Loading...

Unadjusted Closing Price for ARCA Biopharma Inc (ABIO)

Loading...

Share Trading Volume for ARCA Biopharma Inc Shares

Loading...

Compare Performance of ARCA Biopharma Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ABIO

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To ARCA Biopharma Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD127.00B 31.94 20.00

ETFs Containing ABIO

Symbol Name ABIO's Weight Expense Ratio Price(Change) Market Cap

Frequently Asked Questions About ARCA Biopharma Inc (ABIO) Stock

Stock Target Advisor's fundamental analysis for ARCA Biopharma Inc's stock is Slightly Bearish.

Unfortunately we do not have enough data on ABIO's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on ABIO's stock to indicate what its average analyst target is.

ABIO stock's Price/Earning ratio is 26.94. Our analysis grades ABIO stock's Price / Earning ratio at F. This means that ABIO stock's Price/Earning ratio is above 78% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ABIO may be a overvalued for its sector.

The last closing price of ABIO's stock was USD 3.35.

The most recent market capitalization for ABIO is USD 0.05B.

Unfortunately we do not have enough analyst data on ABIO's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains ARCA Biopharma Inc's stock.

As per our most recent records ARCA Biopharma Inc has 4 Employees.

ARCA Biopharma Inc's registered address is Tour Opus 12, Paris, France, 92914. You can get more information about it from ARCA Biopharma Inc's website at https://www.albioma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...